JSB462

Phase 2Small molecule

Novartis

JSB462 is one of 66 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Prostate CancerActive, not recruiting

Prostatic Cancer, Castration-ResistantActive, not recruiting

Castrate Resistant Prostate CancerRecruiting

Metastatic Prostate CancerPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Prostatic Cancer, Castration-ResistantPhase 2

Active, not recruiting

Castrate Resistant Prostate CancerPreclinical

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

JSB462

Novartis

Phase 2

1 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Statin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Metastatic Prostate Cancer

NCT07174063

Q2 2028

Phase 2Active, not recruiting

Prostatic Cancer, Castration-Resistant

NCT07047118

Q4 2030

PreclinicalRecruiting

Castrate Resistant Prostate Cancer

NCT07206056

Q4 2035

Phase 2Recruiting

Prostate Cancer

NCT06991556

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Recruiting· Novartis logo

Novartis·Phase 2·NCT06991556·150 enrolled

Prostatic Cancer, Castration-Resistant1 trial

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Lutetium (177Lu) Vipivotide Tetraxetan in Adult Male Patients With PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC)

Active, not recruiting· Novartis logo

Novartis·Phase 2·NCT07047118·138 enrolled

Metastatic Prostate Cancer1 trial

An Open-label, Single-arm Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JSB462 (Luxdegalutamide) in Japanese Patients With Metastatic Prostate Cancer

Active, not recruiting· Novartis logo

Novartis·Phase 1·NCT07174063·6 enrolled

Castrate Resistant Prostate Cancer1 trial

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Recruiting· Novartis logo

Novartis·Preclinical·NCT07206056·188 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for JSB462. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JSB462 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JSB462. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

JSB462

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Q4 2030

Q4 2035

Trials by Indication[1]

Prostate Cancer1 trial

Prostatic Cancer, Castration-Resistant1 trial

Metastatic Prostate Cancer1 trial

Castrate Resistant Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News